- Home
- SCSC vs ATXS Comparison
SCSC vs ATXS Comparison
Compare SCSC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCSC | ATXS |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.3M | 722.1M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SCSC | ATXS |
|---|---|---|
| Price | $41.83 | $12.87 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 6 |
| Target Price | ★ $43.00 | $24.33 |
| AVG Volume (30 Days) | 156.6K | ★ 1.3M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.79 | N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $3,004,880,000.00 | $706,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $13.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.75 | $3.56 |
| 52 Week High | $53.90 | $13.29 |
Technical Indicators
Market Signals| Indicator | SCSC | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 62.66 |
| Support Level | $40.06 | $12.70 |
| Resistance Level | $43.41 | $13.14 |
| Average True Range (ATR) | 1.18 | 0.23 |
| MACD | 0.14 | -0.06 |
| Stochastic Oscillator | 58.21 | 58.67 |
Price Performance
Historical ComparisonAbout SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.